ArticleLeukemia2023
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
Abstract read
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.Cancers · 2026Guideline
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL.Blood advances · 2026Trial
- Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.Nature communications · 2025Trial
- Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood advances · 2026Review
- Article
- Longitudinal ctDNA tracking by low-pass whole-genome sequencing predicts CAR-T outcomes in B-cell lymphomas.iScience · 2026Article
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Liquid Biopsies and Molecular Imaging for Precise Cancer Management.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects.Hematological oncology · 2025Review
- Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025Review
- Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer.Breast cancer research : BCR · 2025Article
- Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma.Cancers · 2025Article
- Advances and challenges in precision imaging.The Lancet. Oncology · 2025Review
- Follicular lymphoma research: an open dialogue for a collaborative roadmap.Histopathology · 2025Review
- Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.Current pharmaceutical design · 2025Review
- Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL.Frontiers in immunology · 2025Review
- Prospects for liquid biopsy approaches in lymphomas.Leukemia & lymphoma · 2024Review
- Personalised therapy in follicular lymphoma - is the dial turning?Hematological oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Ana Jiménez-Ubieto *Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain. anitiju@hotmail.com.
María Poza *Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Alejandro Martin-MuñozAltum sequencing Co., Madrid, Spain.
Yanira Ruiz-HerediaDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Sara DoradoAltum sequencing Co., Madrid, Spain.ORCID 0000-0002-4144-0315
Gloria FigaredoHospital General Universitario de Toledo, Toledo, Spain.
Juan Manuel Rosa-RosaDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Antonia RodriguezDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Carmen BarcenaHospital Universitario 12 de Octubre, Departamento de Anatomía Patológica, Madrid, Spain.
Laura Parrilla NavamuelHospital General Universitario de Toledo, Toledo, Spain.
Jaime CarrilloAltum sequencing Co., Madrid, Spain.
Ricardo SanchezDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.ORCID 0000-0002-6383-0381
Laura RufianDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Alexandra JuárezDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Margarita RodriguezDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Chongwu WangHosea Precision Medical Technology Co., Ltd., Weihai, Shangdong, China.
Paula de ToledoComputational Science Department, Carlos III University, Madrid, Spain.
Carlos GrandeClínica Universitaria de Navarra, Madrid, Spain.
Manuela MollejoHospital General Universitario de Toledo, Toledo, Spain.
Luis-Felipe CasadoHospital General Universitario de Toledo, Toledo, Spain.
María CalbachoDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.ORCID 0000-0001-8106-4863
Tycho BaumannDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Inmaculada RapadoDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Miguel GallardoDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.ORCID 0000-0002-3699-9130
Pilar SarandesesHospital Universitario 12 de Octubre, Departamento de Medicina Nuclear, Madrid, Spain.
Rosa AyalaDepartment of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Joaquín Martínez-López *Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
Santiago Barrio *Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain. santibarrio0.3@gmail.com.ORCID 0000-0003-0793-3535
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing (NGS) panel. We found trackable mutations in 95% of the lymph node samples and 80% of the liquid biopsy baseline samples. Then, we used an ultra-deep sequencing approach with 2 · 10
Indexed as
Lymphoma, FollicularPositron Emission Tomography Computed TomographyBiomarkersHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyBiomarkers
Identifiers
PMID
36596983What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.